https://www.gotoper.com/publications/ajho/2019/mbcc2019/mbcc19vol1-persephone
MBCC 2019 Volume 1 - PERSEPHONE Trial Offers New Options for HER2+ Disease

March 29, 2024

For patients with HER2-positive disease, the results presented from the phase III PERSEPHONE trial showed patients with early-stage breast cancer could receive shorter treatment to achieve the same outcome. Researchers demonstrated a 6-month course of adjuvant trastuzumab was noninferior for disease-free survival (DFS) compared with the standard 12-month schedule. Overall, the 4-year DFS rate was 89.8% with 12 months of trastuzumab compared with 89.4% for patients on the 6-month arm. A full debrief on the results from this trial and how they inform your practice, will be presented at this year’s meeting.